GalenOps prod · 0.1.0

Runs

3

Escalations

2

Failures

0

Avg duration

4.5 s

Literature & benchmarks

  • ACRO RBQM landscape survey (Barnes et al. 2021) — KRI set: query rate, AE rate, protocol deviations, data-entry lag
  • Centralised statistical monitoring (ICH E6(R2) §5.18.3) — sites compared against the study distribution rather than a fixed cut-off

Run history (3 across all studies)

Newest first, 50 per page. Expand a row for the recorded reasoning and evidence.

Expand When Study Outcome Model Duration Reasoning
2026-09-29 23:42 UTC A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma escalated human claude-sonnet-5 5.5 s Centralized statistical monitoring reviewed 34 sites and 140 patients across 11 KRIs (as of 2014-12-15), following the TransCelerate RBM KRI set and Barnes et al. 2021 RBQM approach. No site reached the composite threshold of 1.5, but three sites triggered the single-KRI rule (|z| ≥ 2.5, per the study's threshold): Royal Perth Hospital (visit-window compliance 50% vs study mean 88%, z=-2.92; missed-visit rate 12% vs mean 3%, z=2.73; risk score 0.496), State Health Centre Oncology Department, Budapest (enrollment 2.11 vs mean 0.67, z=3.36; risk 0.359), and Lviv State Oncological Center (lab flags 18.00 vs mean 9.74, z=2.54; risk 0.34). On-site visits have been proposed for these three sites, pending CRA confirmation; remaining 31 sites are assessed as adequate for remote/centralized monitoring. A human reviewer is asked to confirm or decline the proposed on-site visits for these three flagged sites.
2026-09-29 21:13 UTC A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer completed claude-sonnet-5 4.1 s Across 15 sites (317 patients), centralized statistical monitoring flagged 2 outliers per the single-KRI rule (|z| ≥ 2.5, threshold 2.5). SITE006 (GBR): withdrawal rate 11% vs study mean 2%, z=3.01, exceeding threshold 2.5; also SAE rate 0.68 vs study mean 0.31, z=2.29, and enrollment per open month 1.46 vs study mean 1.71, z=-1.64. Composite 1.173 (below composite threshold 1.5); risk_score 0.444. SITE009 (AUS): lab flags per patient 24.05 vs study mean 16.95, z=2.64, exceeding threshold 2.5. Composite 0.979; risk_score 0.387. Neither breaches the composite threshold of 1.5, but both trip the single-KRI rule. On-site visits are already pending CRA confirmation for both sites; no new review was opened. Remaining 13 sites show remote/centralized monitoring adequate per the deterministic summary. Human decision needed: confirm/schedule the pending CRA on-site visits for SITE006 and SITE009 and review the flagged withdrawal, SAE, and lab-flag patterns.
2026-09-19 08:58 UTC A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer escalated human claude-sonnet-5 4.0 s Centralized statistical monitoring flagged 2 of 15 sites out of 317 patients, using 11 KRIs z-scored against the study population, per the TransCelerate RBM KRI set. SITE006 (GBR) triggered the single-KRI rule (|z| ≥ 2.5) with withdrawal rate 11% vs study mean 2% (z=3.01), SAE rate 0.68 vs mean 0.31 (z=2.29), and enrollment per open month 1.46 vs mean 1.71 (z=-1.64); composite 1.23, risk_score 0.459. SITE009 (AUS) triggered on lab flags per patient 24.05 vs mean 16.95 (z=2.64); composite 1.017, risk_score 0.399. Neither reached the composite threshold of 1.5. On-site visits have been proposed for these two sites (scheduled 2026-10-03), pending CRA confirmation; the remaining 13 sites remain adequate for remote/centralized monitoring. A human reviewer is asked to decide whether to confirm the proposed on-site visits for SITE006 and SITE009.